MedTrace Logo

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

NCT04158856 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-11-12

No results posted yet for this study

Summary

This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus trastuzumab in patients with tumors \<8mm, node-negative, HER2-positive breast cancer.

Conditions

Interventions

DRUG

Pyrotinib

400mg po every day

DRUG

Trastuzumab

Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days

Sponsors & Collaborators

  • xuexin he

    lead OTHER

Principal Investigators

  • Xuexin He, MD · Seaond Affiliated Hospital, Zhejiang University, School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2023-05-31
Completion
2030-05-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04158856 on ClinicalTrials.gov